Prevention of ifosfamide nephrotoxicity by N-acetylcysteine: Clinical pharmacokinetic considerations

Canadian Journal of Clinical Pharmacology

Volumn 14, Issue 2, 2007, Pages

  Chen, Nancy ^a   Aleksa, Katarina ^d   Woodland, Cindy ^d,e   Rieder, Michael ^a,c   Koren, Gideon ^a,b,d,e  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c CHILDREN S HOSPITAL OF WESTERN ONTARIO   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Clinical relevance; Ifosfamide; N acetylcysteine; Nephrotoxicity; Pharmacokinetics; Steady state concentration; Total body clearance

Indexed keywords

ACETYLCYSTEINE; IFOSFAMIDE; PARACETAMOL;

ARTICLE; CELL PROTECTION; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFECT; DRUG MECHANISM; DRUG URINE LEVEL; HUMAN; IN VITRO STUDY; KIDNEY CELL; NEPHROTOXICITY; SINGLE DRUG DOSE; STEADY STATE; SYSTEMATIC REVIEW; TUMOR;

EID: 34548206641     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Schoenike SE, Dana WJ. Ifosfamide and mesna. Clin Pharm 1990;9:179-191.
2. De Kraker J, Ifosfamide in pediatric oncology. Anticancer Drugs 1991;2:339-341.
3. Springate J, Chan K, Lu H, Davies S, Taub M. Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells. In Vitro Cell Dev Biol Anim 1999;35:314-7.
4. Heney D, Wheeldon J, Rushworth P, Chapman C, Lewis IJ, Bailey CC. Progressive renal toxicity due to ifosfamide. Arch Dis Child 1991;66:966-70.
5. Loebstein R, Koren G. Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors. Pediatrics 1998;101:E8-E12.
6. Skinner R. Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol 2003;41:190-197.
7. Loebstein R, Atanackovic G, Bishai R et al. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 1999;39:454-61.
8. Skinner R, Sharkey IM, Pearson AD, Craft AW. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 1993;11:173-90.
9. Rossi R, Pleyer J, Schafers P, Kuhn N, Kleta R, Deufel T. Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients. Med Padiatr Oncol 1999;32:177-182.
10. Chen N, Aleksa K, Woodland C, Rieder MJ, Koren G. The Effect of N-Acetylcysteine on Ifosfamide-Induced Nephrotoxicity. Abstract presented at 3rd Canadian Therapeutics Congress. Canadian Journal of Clinical Pharmacology 2006;13:e189.
11. Marzullo L. An update of N-acetylcysteine treatment for acute acetaminophen toxicity in children. Curr Opin Pediatr 2005;17:239-45.
12. Kelly GS. Clinical applications of N-acetylcysteine. Altern Med Rev 1998;3:114-27.
13. De Vries N, De Flora S. N-acetyl-l-cysteine. J Cell Biochem Suppl 1993;17:270-7.
14. De Flora S, Izzotti A, D'Agostini F, Cesarone CF. Antioxidant activity and other mechanisms of thiols involved in chemoprevention of mutation and cancer. Am J Med 1991;91:122S-130S.
15. Borgstrom L, Kagedal B, Paulsen O. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 1986;31:217-22.
16. Addis T, Watanabe CK. The volume of urine in young healthy adults on a constant diet. J. Biol. Chem 1961;27:267-272
17. Ahola T, Fellman V, Laaksonen R, Laitila J, Lapatto R, Neuvonen PJ, Raivio KO. Pharmacokinetics of intravenous N-acetylcysteine in pre-term new-born infants. Eur J Clin Pharmacol 1999;55:645-50.
18. Prescott LF, Donovan JW, Jarvie DR, Proudfoot AT. The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. Eur J Clin Pharmacol 1989;37:501-6.
19. Jones AL, Jarvie DR, Simpson D, Hayes PC, Prescott LF. Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease. Aliment Pharmacol Ther 1997;11:787-91.
20. Olsson B, Johansson M, Gabrielsson J, Bolme P. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol 1988;34:77-82.
21. Brown M, Bjorksten A, Medved I, McKenna M. Pharmacokinetics of intravenous N-acetylcysteine in men at rest and during exercise. Eur J Clin Pharmacol 2004;60:717-23.
22. Holdiness MR. Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet 1991;20:123-34.
23. De Caro L, Ghizzi A, Costa R, Longo A, Ventresca GP, Lodola E. Pharmacokinetics and bioavailability of oral acetylcysteine in healthy volunteers. Arzneimittelforschung 1989;39:382-6.
24. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999;37:485-505.
25. Burgunder JM, Varriale A, Lauterburg BH. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol 1989;36:127-31.
26. Morgan LR, Holdiness MR, Gillen LE. N-acetylcysteine: its bioavailability and interaction with ifosfamide metabolites. Semin Oncol 1983;10:56-61.